2020. In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells. Brazilian Journal of Pharmaceutical Sciences. 56, (Dec. 2020), e18254. DOI:https://doi.org/10.1590/s2175-97902019000318254.